Maxcyte annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Maxcyte Stock-Based Compensation Growth & History (MXCT)
Maxcyte's stock-based compensation was $9.2M for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.2M | −$3.9M | −29.58% |
| 2024 | 2024-12-31 | $13.1M | −$896,000 | −6.41% |
| 2023 | 2023-12-31 | $14.0M | $2.2M | +18.95% |
| 2022 | 2022-12-31 | $11.8M | $3.8M | +47.66% |
| 2021 | 2021-12-31 | $8.0M | $5.5M | +221.98% |
| 2020 | 2020-12-31 | $2.5M | $719,700 | +41.08% |
| 2019 | 2019-12-31 | $1.8M | — | — |
Maxcyte quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.2M | −$2.4M | −66.99% |
| Q1 2026 | 2026-03-31 | $1.1M | −$1.9M | −62.45% |
| Q4 2025 | 2025-12-31 | $706,000 | −$2.4M | −77.47% |
| Q3 2025 | 2025-09-30 | $2.0M | −$1.4M | −42.02% |
| Q2 2025 | 2025-06-30 | $3.5M | −$50,000 | −1.40% |
| Q1 2025 | 2025-03-31 | $3.0M | $24,000 | +0.80% |
| Q4 2024 | 2024-12-31 | $3.1M | −$440,000 | −12.31% |
| Q3 2024 | 2024-09-30 | $3.4M | −$239,000 | −6.62% |
| Q2 2024 | 2024-06-30 | $3.6M | $45,000 | +1.28% |
| Q1 2024 | 2024-03-31 | $3.0M | −$262,000 | −8.00% |
| Q4 2023 | 2023-12-31 | $3.6M | $455,800 | +14.62% |
| Q3 2023 | 2023-09-30 | $3.6M | $410,400 | +12.83% |
| Q2 2023 | 2023-06-30 | $3.5M | $546,200 | +18.37% |
| Q1 2023 | 2023-03-31 | $3.3M | $814,600 | +33.08% |
| Q4 2022 | 2022-12-31 | $3.1M | $669,800 | +27.36% |
| Q3 2022 | 2022-09-30 | $3.2M | $913,200 | +39.96% |
| Q2 2022 | 2022-06-30 | $3.0M | $1.1M | +56.04% |
| Q1 2022 | 2022-03-31 | $2.5M | $1.1M | +86.57% |
| Q4 2021 | 2021-12-31 | $2.4M | — | — |
| Q3 2021 | 2021-09-30 | $2.3M | $1.7M | +282.17% |
| Q2 2021 | 2021-06-30 | $1.9M | $1.3M | +240.82% |
| Q1 2021 | 2021-03-31 | $1.3M | — | — |
| Q3 2020 | 2020-09-30 | $598,000 | — | — |
| Q2 2020 | 2020-06-30 | $559,000 | — | — |
Maxcyte stock-based compensation trends
Over the last five fiscal years, Maxcyte's stock-based compensation increased from $2.5M to $9.2M, a change of $6.7M. The latest reported quarter, Q2 2026, shows $1.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte source filings ↗